Newly Diagnosed Lupus Erythematosus Could Potentially Be Drug Induced
A new case of cutaneous lupus erythematosus or systemic lupus erythematosus could potentially be drug induced.
Systemic Lupus Erythematosus
MPR Weekly Dose Podcast Episode 44
This week: The government makes a $1.95 billion deal for a COVID-19 vaccine; Promising data from the Oxford vaccine trial; The CDC retakes control of COVID-19 data; Novel calcineurin inhibitor for lupus nephritis gets priority review; And there’s new treatment for narcolepsy.
Voclosporin Granted Priority Review for Lupus Nephritis
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.
Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
Telitacicept Fast-Tracked for Systemic Lupus Erythematosus
The FDA has granted Fast Track designation to telitacicept (RC18; RemeGen) for the treatment of systemic lupus erythematosus.
Doctors, Hospitals, Pharmacies Warned Not to Stockpile Meds
Professional societies issue stern warning not to inappropriately prescribe meds for COVID-19.
Anifrolumab Improves Response at 52 Weeks in Lupus
Rate of composite response showing reduced disease activity higher with anifrolumab versus placebo
Glucocorticoid Use Associated With Increased Risk for Cardiovascular Disease in SLE
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Diagnoses of RA, SLE Linked to Increased Opioid Overdose Hospitalization Risk
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
